The beneficial effects of glycoprotein IIb/IIIa receptor antagonists in preventing ischemic complications during percutaneous coronary intervention have been established in a series of controlled ...
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Coronary heart disease (CHD) is the most common cause of death in the UK. It is a progressive disease. The first presenting symptom is often stable angina (pain in the chest on exertion), which may ...
Please provide your email address to receive an email when new articles are posted on . Medicure announced it has received FDA approval for a premixed bolus dose of its glycoprotein IIb/IIIa inhibitor ...
The low rate of intracranial hemorrhage in these trials suggests that, at least in the patient population included in clinical trials, there is no increased risk in comparison to control arms of ...
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has acute coronary syndromes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results